Anxiety Disorders And Depression Treatment Market To Reach $15.88 Billion By 2030

Anxiety Disorders And Depression Treatment Market Growth & Trends

The global anxiety disorders and depression treatment market is expected to reach a value of USD 15.88 billion by 2030. The market is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

 Request a free sample copy or view report summary: Anxiety Disorders And Depression Treatment Market Report

Anxiety Disorders And Depression Treatment Market Report Highlights

• Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane

• Patent expiration of branded medicines and the introduction of generic biosimilars, which are cost-effective, are responsible for the shrinking market of antidepressants

• On the other hand, the introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, is predicted to fuel the demand for therapeutics in the coming years

• Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs

• North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region

• The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Anxiety Disorders And Depression Treatment Market Segmentation

Grand View Research has segmented the global anxiety disorders and depression treatment market by drugs, indication, distribution channel and region:

Anxiety Disorder And Depression Treatment Drugs Outlook (Revenue, USD Million, 2018 - 2030)

• Antidepressants

• Anxiolytics

• Anticonvulsants

• Noradrenergic Agents

• Atypical Antipsychotics

Anxiety Disorder And Depression Treatment Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Depression

• Anxiety

Anxiety Disorder And Depression Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Anxiety Disorder And Depression Treatment Regional Outlook (Revenue, USD million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List Of Key Players in the Anxiety Disorders And Depression Treatment Market

• Pfizer Inc.

• H. Lundbeck A/S

• Glaxo SmithKline Pharmaceuticals Ltd.

• Merck & Co., Inc.

• Eli Lilly & Company

• AstraZeneca

• Bristol-Myers Squibb

• Johnson & Johnson

• AbbVie Inc.

• Sanofi